PerkinElmer Expands Cell Biology Capabilities with Nexcelom Bioscience Acquisition

BioPharm International Editors

The acquisition gives PerkinElmer access to Nexcelom Bioscience’s complementary cell counting and analysis capabilities and enhances its QA/QC capabilities.

PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience, a US-based provider of image cytometry products for cell analysis, for $260 Million in cash. The transaction is expected to close in the second quarter of 2021, PerkinElmer announced in a May 12, 2021 press release.

Nexcelom provides automated cell counting instruments, image cytometry workstations, assays, and a variety of cell reagents. It also provides consumables and fit-for-purpose cell-counting method selection and development instructions that are compliant with ISO Cell Counting Standards and that aid in the development of cell and gene and immuno-oncology therapies, virology drugs, and vaccines.

The agreement follows PerkinElmer’s recent $383 million acquisition of UK-based Horizon Discovery Group, a cell engineering company specializing in gene editing and gene modulation (1).

“We are looking forward to bringing Nexcelom’s expertise and technologies in drug development together with our passion and solutions for drug discovery. This combination will expand our efforts to help academic, government, and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies,” said Prahlad Singh, president and CEO of PerkinElmer, in the company press release.

“Our team is very excited to be joining forces with PerkinElmer to help scientists resolve some of today’s most pressing health challenges through modernizing cell-based assays using the most advanced cell models. Our organization has a deep commitment to innovation, and we are looking forward to continuing to grow our technology and customer footprint in combination with PerkinElmer’s strong global presence and infrastructure,” added Peter Li, president and CEO of Nexcelom, in the press release.

Source: PerkinElmer

Reference

1. PerkinElmer, “PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million),” Press Release, Nov. 2, 2020.